Home›Stock Screener›Kimia Biosciences

Kimia Biosciences Share Price Today | Stock Price & Kimia Biosciences Share Screener

KIMIABL Pharmaceuticals
Live Share Price BSE
₹31.99
▲ 0.99 (3.19%)
2026-10-05 00:00:00

As of October 5, 2026, the live Kimia Biosciences share price (BSE: KIMIABL) is ₹31.99, up 3.19% from the previous close, with shares trading between ₹31.00 and ₹32.00 in today's trading session, and a 52-week range of ₹23.55–₹39.95. Check KIMIABL 52-week performance for the annual price range and momentum. Use the Kimia Biosciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Kimia Biosciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹113 and net income of ₹7, with EBITDA of ₹15, an operating margin of 13.0% and a profit margin of 6.2%.

Kimia Biosciences Market Cap ₹147.88 Cr.
KIMIABL P/E Ratio (TTM) 20.39
Kimia Biosciences P/B Ratio 8.28
EPS (TTM) ₹1.64
Dividend Yield -
Debt to Equity 2.45
KIMIABL 52 Week High ₹39.95
Kimia Biosciences 52 Week Low ₹23.55
Operating Margin 13.00%
Profit Margin 6.19%
KIMIABL Revenue (TTM) ₹113.00
EBITDA ₹15.00
Net Income ₹7.00
Total Assets ₹103.00
Total Equity ₹18.00

Kimia Biosciences Share Price Chart

Track the current stock price of Kimia Biosciences with an interactive chart. Analyse KIMIABL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Kimia Biosciences stock quote in one place.

The quote of ₹31.99 sits between the 52-week low of ₹23.55 and the 52-week high of ₹39.95, and the latest session moved 3.19% from the previous close.

Kimia Biosciences Company Profile - Fundamental Screener

Screen Kimia Biosciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for KIMIABL shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE285U01025.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE285U01025

Kimia Biosciences Balance Sheet Screener

Screen KIMIABL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹103, down from ₹111 in 2025.

Latest statistics put total assets at ₹103 and shareholder funds at ₹18, with a leverage ratio of 2.45.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 103 111 100 121 110 107 86 65 58 12
Current Assets 64 75 61 83 73 72 61 48 43 2
Fixed Assets 37 33 32 34 35 28 18 16 13 7

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 24 19 30 40 33 37 34 29 25 9
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 18 10 0 6 15 18 13 6 2 -5
Share Capital 5 5 5 5 5 5 5 2 2 7
Reserves & Surplus 13 5 -4 1 10 14 9 2 -2 -12

Kimia Biosciences Income Statement Screener - Profit & Revenue Analysis

Screen Kimia Biosciences income statement and profit fundamentals. Analyze KIMIABL quarterly results. Kimia Biosciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹113 and net profit was ₹7, equal to earnings per unit of ₹1.60, at an operating margin of 13%.

In that period expenses were ₹98, interest cost ₹3 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹117 and net profit of ₹7.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 113 117 120 107 130 126 135 107 95 77 2 0 2
Expenses 98 101 99 105 134 124 124 102 88 74 2 4 4

Operating Costs and Margins

EBITDA 15 16 22 1 -4 2 11 5 7 3 0 -3 -1
Operating Profit % 13.00% 12.00% 17.00% 0.00% -4.00% 1.00% 6.00% 4.00% 6.00% 3.00% -67.00% -1759.00% -110.00%
Depreciation 4 4 3 3 3 3 2 2 1 1 0 0 0
Interest 3 4 5 5 4 4 3 3 2 1 0 1 0

Profit and Earnings

Profit Before Tax 8 9 14 -7 -12 -5 6 1 4 2 -1 -4 -2
Tax 0 1 4 -2 -3 -1 0 0 0 0 0 0 0
Net Profit 7 7 10 -5 -9 -4 5 1 4 2 -1 -4 -2
EPS 1.60 1.64 2.04 -1.12 -1.98 -0.78 1.08 0.33 2.64 1.14 -1.26 -5.49 -2.31

Kimia Biosciences Cash Flow Screener - Liquidity Fundamentals

Screen KIMIABL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹11.

Over the same period, investing activities used ₹8 and financing activities used ₹3.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 11 21 15 -7 8 6 0 -3 -7 -1
Investing Activities -8 -5 -2 -3 -1 -14 -9 -2 -2 -6

Financing and Net Cash

Financing Activities -3 -17 -13 10 -8 8 9 4 10 7
Net Cash Flow 0 0 0 0 0 0 0 -1 1 0

Kimia Biosciences Shareholding Pattern Screener

See Kimia Biosciences shareholding pattern with promoter, FII, and DII holdings. Check Kimia Biosciences promoter holding and ownership changes for KIMIABL on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 74.94%, foreign institutions 0.00%, domestic institutions 0.38% and the public 22.88%, spread across 12,775 shareholders.

The shareholder count was 12,775 in 2026-Mar, compared with 12,775 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.38% 0.38% 0.38% 0.38% 0.38% 0.38% 0.38% 0.38%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 22.88% 22.88% 23.04% 23.04% 22.93% 22.92% 23.05% 23.05%
Other Holding 1.80% 1.80% 1.64% 1.64% 1.75% 1.75% 1.63% 1.63%
Shareholder Count 12,775 12,775 12,278 12,200 12,616 12,751 12,110 12,023

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Kimia Biosciences. Kimia Biosciences dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Kimia Biosciences.

Kimia Biosciences Stock Index Membership - Nifty & Sensex

See which indices include Kimia Biosciences stock. Check KIMIABL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Kimia Biosciences is not part of any tracked indices.
Only major market indices are tracked in our system.

Kimia Biosciences Market Events Screener - Corporate Actions

Get Kimia Biosciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Kimia Biosciences stock events that may affect KIMIABL share price, along with derivatives, futures and options activity and sector gainers.

13 corporate actions are listed, the most recent entry being Annual General Meeting dated September 28, 2026, with a record date of September 28, 2026.

It is followed by Quarterly Result Announcement dated August 10, 2026 and Quarterly Result Announcement dated May 29, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-28 2026-09-28 Annual General Meeting NA 6.77%
2026-08-10 2026-08-10 Quarterly Result Announcement NA -5.31%
2026-05-29 2026-05-29 Quarterly Result Announcement NA 2.28%
2026-02-14 2026-02-14 Quarterly Result Announcement NA 25.71%
2025-12-30 2025-12-30 Annual General Meeting NA -9.62%
2025-11-14 2025-11-14 Quarterly Result Announcement NA 0.25%
2025-09-30 2025-09-30 Annual General Meeting NA -1.53%
2025-08-14 2025-08-14 Quarterly Result Announcement NA -7.15%
2025-07-22 2025-07-22 Extraordinary General Meeting NA 39.79%
2025-05-26 2025-05-26 Quarterly Result Announcement NA 3.95%
2025-02-13 2025-02-13 Quarterly Result Announcement NA -8.06%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -3.78%
2019-01-04 2019-01-04 Change Of Name NA 0.00%

Kimia Biosciences Competitors Screener - Peer Stocks Comparison

Screen KIMIABL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 428,641 35.84 61,674 12.69% 11,565 36.68
Divis Laboratories 242,293 84.36 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 179,944 84.01 13,886 20.34% 2,138 41.12
Zydus Life Science 112,828 24.88 27,658 17.64% 5,026 47.64
Cipla 107,574 32.42 29,045 2.24% 3,870 34.78
Laurus Labs 105,745 98.56 6,868 22.01% 890 58.70
Mankind Pharma 103,282 50.48 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,003 31.47 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,313 25.97 34,145 5.56% 3,503 50.30
Lupin 91,975 16.71 29,039 26.75% 5,356 31.59

Kimia Biosciences Company Announcements - News & Reports Screener

Screen KIMIABL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated September 30, 2026.

The next most recent announcements are dated September 30, 2026 and September 29, 2026.

Date Update Actions
2026-09-30 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-30 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-29 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-27 Closure of Trading Window -
2026-09-07 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-04 Reg. 34 (1) Annual Report. -
2026-09-04 Intimation Of Cut-Off Date/ Record Date E-Voting And AGM Date For The 33Rd Annual General Meeting. -
2026-09-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-04 Intimation Of 33Rd Annual General Meeting Of The Company Proposed To Be Held On September 28 2026 At 3:00 P.M. Through Video Conferencing/Other Audio Visual Means. -
2026-09-03 Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On September 03 2026 Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. -
2026-08-12 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-10 Unaudited Financial Results For The First Quarter Ended June 30 2026 -
2026-08-10 Board Meeting Outcome for Outcome Of Board Meeting Held On August 10 2026 (Monday) -
2026-08-03 Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations 2015 -Intimation Of Meeting Of Board Of Directors. -
2026-08-01 Announcement under Regulation 30 (LODR)-Change in Management -
2026-08-01 Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 1 2026 Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-06-27 Closure of Trading Window -
2026-06-01 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-29 Outcome Of The Board Meeting Held On 29 May 2026 -
2026-05-20 Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations 2015 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹31.99, within a 52-week range of ₹23.55 to ₹39.95. The P/E ratio is 20.39 and the P/B ratio is 8.28, with earnings per unit of ₹1.64. Market capitalisation stands at ₹147.88 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.